A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas

The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma. Currently, there are no FDA-approved treatments for relapsed CNS lymphoma. Although acalabrutinib has not been approved for the treatment of CNS lymphoma, it was approved for the treatment of another type of lymphoma (mantle cell), by the Food and Drug Administration (FDA). Acalabrutinib acts similar to another cancer drug called ibrutinib. lbrutinib was tested in several research trials for the management of CNS lymphomas, and the results were promising. Acalabrutinib and ibrutinib attack a similar target found in CNS lymphoma. Acalabrutinib may do a better job in attacking this target than ibrutinib. The study doctors will be looking to see if acalabrutinib can shrink cancer cells.

NCT Number	NCT04548648
Lead Sponsor	UNC Lineberger Comprehensive Cancer Center Collaborators: AstraZeneca
Conditions	Central Nervous System Lymphoma
Enrollment	10 participants
Start Date	2020-10-15
Primary Completion	2025-05-14 (estimated)
Study Completion	2030-03-14 (estimated)
Updated on ClinicalTrials.gov	2026-06-10